DOCSLIB.ORG

Effects of Prior Treatment with Salmeterol and Formoterol on Airway

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Prior Treatment with Salmeterol and Formoterol on Airway Thorax 1996;51:585-589 585 Effects of prior treatment with salmeterol and formoterol on airway and systemic 2 responses to fenoterol Thorax: first published as 10.1136/thx.51.6.585 on 1 June 1996. Downloaded from Alison Grove, Brian J Lipworth Abstract response curves to repeated doses of Background - Previous studies have fenoterol in stable asthmatic patients. shown that both salmeterol and formoterol (Thorax 1996;51:585-589) act as partial P2 receptor agonists in terms of antagonising the extrapulmonary re- Keywords: salmeterol, formoterol, fenoterol, partial sponses to fenoterol in normal subjects. agonist, bronchodilation, asthma. The aim ofthe present study was to extend previous observations in evaluating the Salmeterol and formoterol are both long acting effect of prior treatment with salmeterol P2 receptor agonists used in the treatment of and formoterol on bronchodilator re- asthma. It has been shown in vitro that sal- sponses to fenoterol, a full P2 receptor meterol is a partial 32 receptor agonist'2 and, agonist, in patients with asthma. even at high concentrations, it is unable to Methods - Ten stable asthmatic patients produce the maximal bronchorelaxant response of mean (SE) age 37 (3.7) years and forced elicited by a full agonist such as isoprenaline. expiratory volume in one second (FEV,) This difference can be expressed in terms of 59-5 (4-1)% of predicted completed the the intrinsic efficacy of the agonist, with a full study. One hour after inhaling single doses agonist such as isoprenaline nominally being ofplacebo, salmeterol 25 jg, or formoterol given an intrinsic activity of 1. Other agonists 12 jtg, dose-response curves to repeated can then be compared with this standard. In doses of inhaled fenoterol were con- vitro studies have shown that the intrinsic ac- structed (cumulative doses of100-3200 pg). tivity of salmeterol is of the order of 0 71 Measurements of airway and systemic P2 compared with isoprenaline.3 The intrinsic ac- receptor mediated responses were made tivity of formoterol is also lower than that at baseline, after inhalation of placebo, of isoprenaline with a value of 096,3 thus http://thorax.bmj.com/ salmeterol, or formoterol, and after each formoterol is also a partial agonist - albeit a dose of fenoterol. strong one. Results - Salmeterol and formoterol pro- From first principles it can be predicted that duced significant bronchodilation com- the presence of a partial agonist may inhibit pared with placebo (mean difference and the effects of an agonist with greater intrinsic 95% CI compared with placebo): FEV,, activity.4 In this respect we have previously salmeterol 0-41 (95% CI 0-13 to 0.69) 1, for- shown that oral salbutamol inhibits the effects moterol 0-47 (95% CI 0-19 to 0-75) 1. Sal- of endogenous adrenaline at extrapulmonary on October 2, 2021 by guest. Protected copyright. meterol and formoterol had no significant 12 receptors in normal subjects.5 In addition effect on systemic responses compared we have demonstrated that inhaled salmeterol with placebo. There were no significant and formoterol antagonise the extrapulmonary differences in peak airway responses to P2 receptor responses to endogenous adrenaline fenoterol after treatment with salmeterol and to exogenous inhaled fenoterol, also in or formoterol compared with placebo normal subjects.6 (mean (pooled SE)): FEV,, placebo The aim of the present study was to extend 2.84(0-03)1, salmeterol 2.87 (0.03)1, and the findings of these previous studies in order formoterol 2-88 (0.03)1. There were no sig- to assess whether prior treatment with sal- nificant differences in the area under the meterol or formoterol affects the airway and dose-response curve for any of the para- systemic 12 responses to repeated doses of in- Department of meters during the dose-response curve fol- haled fenoterol in asthmatic subjects. Fenoterol Clinical lowing treatment with salmeterol or was chosen to construct the dose-response Pharmacology, formoterol compared with There curves as it is known to be a full agonist with University of Dundee, placebo. intrinsic Ninewells Hospital and was no difference in the slope of the dose- greater activity than either salmeterol Medical School, response curves to fenoterol for FEVy or or formoterol. Low doses of salmeterol and Dundee DD1 9SY, UK forced expiratory flow after formoterol were used so as not to produce A Grove (FEF2575) maximal bronchodilator activity prior to ad- B J Lipworth treatment with salmeterol or formoterol ministering fenoterol. Correspondence to: compared with placebo, although there Dr A Grove. was a significant (p<005) attenuation of Received 15 August 1995 the slope in the dose-response curve for Methods Returned to authors 4 December 1995 the peak expiratory flow rate (PEFR). SUBJECTS Revised version received Conclusions - Prior treatment with low Ten stable asthmatic patients (five women) 10 January 1996 Accepted for publication doses of salmeterol or formoterol does not of mean (SE) age 37 (3 7) years and forced 18 January 1996 significantly alter bronchodilator dose- expiratory volume in one second (FEV,) 2'04 586 Grove, Lipworth (0 23) 1,59 5 (4 1)% ofpredicted normal, com- acic Society criteria' using a Vitalograph com- pleted the study. All patients were diagnosed as pact spirometer with pneumotachograph head having asthma according to American Thoracic and pressure transducer, and on-line computer Society criteria.8 At an initial screening visit assisted determination of FEVL, FEF2, ,-, and patients were required to have an FEV, of PEFR. Forced expiratory manoeuvres were Thorax: first published as 10.1136/thx.51.6.585 on 1 June 1996. Downloaded from less than 80% of predicted normal, and to performed from total lung capacity to residual demonstrate at least 15% reversibility to in- volume with measures being taken according haled fenoterol 200 jg (Berotec 200 metered to best test criteria. dose inhaler; Boehringer Ingelheim, Bracknell, Berkshire, UK). In addition, all subjects were required to have a normal physical ex- Extrapulmonary responses amination, 12 lead ECG, haematology and A standard lead II electrocardiogram was mon- biochemical screen. All subjects gave written itored and recorded with a Hewlett-Packard informed consent to participate in the study ECG monitor and printer (Palo Alto, California, which had been approved by the Tayside com- USA) with paper speed set at 25 mm/s. Heart mittee for medical ethics. At the time of the rate was calculated from the mean of five con- study all 10 patients were using inhaled cortico- secutive R-R intervals. steroids in doses of400-2400,g daily, together Finger tremor was recorded by a previously with inhaled short acting bronchodilators on validated method10 using an accelerometer an as required basis. In addition, four patients transducer (Entran Ltd, Ealing, UK). Four were oral recordings were made at each measurement taking theophylline preparations. and the results were stored on computer for subsequent analysis of total tremor power >2 Hz (mg2/s) using computer assisted auto- PROTOCOL Patients attended the laboratory between 08.00 covariance. The mean of three consistent re- and 09.00 hours on three occasions separated cordings was subsequently used in the analysis. by at least one week. Before each visit broncho- Serum potassium levels were measured by dilators were withheld for an appropriate period flame photometry (IL943 analyser, Instru- of time (that is, 48 hours for theophylline pre- mentation Laboratory Ltd, Warrington, UK) parations and eight hours for short acting 32 with analysis being performed in batches at the agonists). A cannula was inserted into a forearm end of the study, and samples being assayed vein to facilitate venous blood sampling. After in duplicate. The coefficients of variation for 30 minutes supine rest, baseline measurements analytical imprecision within and between as- of heart rate, postural finger tremor, serum says were 0 41% and 1-04%, respectively. The potassium levels, and spirometric parameters normal reference range for serum potassium were performed. was required to be levels in our laboratory is 3 5-555 mmol/l. FEV, http://thorax.bmj.com/ within 15% of that recorded at the initial screening visit. Subjects were then randomised STATISTICAL ANALYSIS to receive inhaled placebo, salmeterol 25 jtg Data for finger tremor were transformed using (Serevent metered dose inhaler, 25 jtg per actu- logarithm to base 10 to achieve conformation ation; Allen and Hanburys, Uxbridge, Middle- with a normal distribution. Data were then sex, UK), or formoterol 12,ug (Foradil metered analysed using a Statgraphics software package dose inhaler, 12 gg per actuation, Ciba Geigy (STSC Software Publishing Group, Rockville, AG Basel, Switzerland) in a single blind cross- USA). Baseline values, and values following over fashion. All drugs were administered via inhalation of placebo, salmeterol, and for- on October 2, 2021 by guest. Protected copyright. a large volume spacer device in an attempt to moterol, were compared by multifactorial anal- maximise lung delivery. After one hour further ysis ofvariance (MANOVA). Where the overall measurements of airway and systemic para- MANOVA was significant, Duncan's multiple meters were made. A dose-response curve to range testing was used to establish where inhaled fenoterol (Berotec metered dose in- differences were significant. Peak values halers, 100 jig and 200 jig per actuation) was achieved during the dose-response curve by constructed using doses of 100 jig, 100 pg, each individual were obtained, regardless of 200 jg, 400 jig, 800 jg, and 1600 jg- that the doses at which they occurred, and were is, a total cumulative dose of 3200,g. The compared by MANOVA and Duncan's mul- fenoterol was also administered via the large tiple range testing. Analysis of the responses at volume spacer device. Dose increments were individual doses from the dose-response curve given at 20 minute intervals with measurements was not performed in order not to confound being made 15 minutes after each dose.
Load more

Recommended publications
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203975s000 SUMMARY REVIEW SUMMARY REVIEW OF REGULATORY ACTION Date: November 26, 2013 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Subject: Division Director Summary Review NDA Number: 20-3975 Applicant Name: GlaxoSmithKline Date of Submission: December 18, 2012 PDUFA Goal Date: December 18, 2013 Proprietary Name: Anoro Ellipta Established Name: Umeclidinium and vilanterol Dosage form: Inhalation Powder (inhaler contains 2 double-foil blister strips, each with 30 blisters containing powder for oral inhalation) Strength: Umeclidinium 62.5 mcg per blister and vilanterol 25 mcg per blister Proposed Indications: Maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) Action: Approval 1. Introduction GlaxoSmithKline (GSK) submitted this 505(b)(1) new drug application for use of Anoro Ellipta (umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder) for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The proposed dose is one inhalation (umeclidinium 62.5 mcg and vilanterol 25 mcg) once daily. The application is based on clinical efficacy and safety studies. This summary review will provide an overview of the application, with a focus on the clinical efficacy and safety studies. 2. Background There are several drug classes available for the relief of airflow obstruction in patients with COPD. These include short- and long-acting beta-2 adrenergic agonists, short- and long-acting anticholinergics, combination products containing beta-2 adrenergic agonists and anticholinergics, combination of long-acting beta-2 adrenergic agonists and corticosteroids, methylxanthines, and phosphodiesterase-4 (PDE4) inhibitors.
    [Show full text]
  • Orciprenaline Sulphate (Alupent): Planned Withdrawal from the UK Market Following a Risk-Benefit Analysis
    MHRA PUBLIC ASSESSMENT REPORT Orciprenaline sulphate (Alupent): planned withdrawal from the UK market following a risk-benefit analysis November 2009 Executive summary 2 1. Introduction 3 2. Summary of data 3 2.1 Clinical pharmacology 3 2.2 Efficacy 3 2.3 Safety 4 3. Conclusions 8 4. References 9 5. Glossary 10 1 EXECUTIVE SUMMARY (Please note that this summary is intended to be accessible to all members of the public, including health professionals) Background The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for regulating the effectiveness and safety of medicines and medical devices in the UK. We continually review the safety of all medicines in the UK, and inform healthcare professionals and the public of the latest safety updates. In our Public Assessment Reports, we discuss the evidence for a safety issue with a particular drug or drug class, and changes made to the product information for the drug on the basis of this evidence, which will help safeguard public health. This MHRA Public Assessment Report discusses a review of the risks and benefits of a medicine called orciprenaline sulphate. Orciprenaline sulphate is available for oral administration as a syrup used to treat reversible airways obstructiona, which is a symptom of asthmab and chronic obstructive pulmonary diseasec. It acts on specific areas in the body called β- receptors, which relaxes the muscles used for breathing and opens the airways in the lungs. Orciprenaline sulphate was licensed in 1972 and is marketed in the UK under the brand name Alupent Syrup. As with any medicine, the use of orciprenaline sulphate may lead to adverse reactions (side-effects) in some individuals, which are described in the product information, including the patient information leaflet (see the Electronic Medicines Compendium (product information) website).
    [Show full text]
  • Case-Control Study Ofprescribed Fenoterol
    170 Thorax 1990;45:170-175 Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81 Thorax: first published as 10.1136/thx.45.3.170 on 1 March 1990. Downloaded from N Pearce, J Grainger, M Atkinson, J Crane, C Burgess, C Culling, H Windom, R Beasley Abstract A recent New Zealand case-control study,' A previous New Zealand case-control conducted by our group, tested the hypothesis study of asthma deaths in the 5-45 year that the unsupervised self administration of age group during 1981-3 found that pres- fenoterol by inhalation increases the risk of cription of fenoterol (by metered dose death from asthma. This hypothesis arose inhaler) was associated with an increased primarily from epidemiological evidence link- risk of death in patients with severe ing the sale of fenoterol to the epidemic of asthma. One major criticism ofthis study deaths from asthma that New Zealand has was that drug data for the cases and experienced since the late 1970s,' 2 and controls came from different sources. A experimental evidence that fenoterol is a less new case-control design has been used to selective beta2 agonist than salbutamol, the evaluate the same hypothesis, with a dif- most commonly used beta agonist.3 The possi- ferent set of asthma deaths, the same ble mechanisms ofaction remain to be clarified, source for drug information being used but several potential mechanisms are apparent; for both cases and controls. This depen- these depend on whether the association is with ded on identifying deaths from asthma long term use of fenoterol or use in the acute during 1977-81 from national mortality attack.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Salmeterol Enhances the Cardiac Response to Gene Therapy in Pompe Disease
    Salmeterol enhances the cardiac response to gene therapy in Pompe disease Sang-oh Han1, Songtao Li1, and Dwight D. Koeberl1* 1Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC *To whom correspondence should be addressed at: Box 103856, Duke University Medical Center, Durham, NC 27710. Running title: Small molecules for Pompe disease Page 2 ABSTRACT Enzyme replacement therapy (ERT) with recombinant human (rh) acid -glucosidase (GAA ) has prolonged the survival of patients. However, the paucity of cation-independent mannose-6- phosphate receptor (CI-MPR) in skeletal muscle, where it is needed to take up rhGAA, correlated with a poor response to ERT by muscle in Pompe disease. Clenbuterol, a selective 2 receptor agonist, enhanced the CI-MPR expression in striated muscle through Igf-1 mediated muscle hypertrophy, which correlated with increased CI-MPR (also the Igf-2 receptor) expression. In this study we have evaluated 4 new drugs in GAA knockout (KO) mice in combination with an adeno-associated virus (AAV) vector encoding human GAA, 3 alternative 2 agonists and dehydroepiandrosterone (DHEA). Mice were injected with AAV2/9-CBhGAA (1E+11 vector particles) at a dose previously found to be partially effective at clearing glycogen storage from the heart. Heart GAA activity was significantly increased by either salmeterol (p<0.01) or DHEA (p<0.05), in comparison with untreated mice. Furthermore, glycogen content was reduced in the heart by treatment with DHEA (p<0.001), salmeterol (p<0.05), formoterol (p<0.01), or clenbuterol (p<0.01) in combination with the AAV vector, in comparison with untreated GAA-KO mice.
    [Show full text]
  • Project Review
    PROJECT REVIEW ”Development of analytical methods for the quantitative determination of beta-agonists and determination of detection times after therapeutic use” Beta-agonists are substances frequently used for the treatment of asthma. These drugs are most frequently administered by inhalation of aerosol, powder or nebulised solution. Besides the main pharmacological effect, at higher doses, side effects of the use of these products result in anabolic action. Hence, beta-2- agonists might be misused for their stimulating effect on respiration and growth promoting action when administered in higher doses. As a result, WADA has prohibited the use of these drugs in sports. Exceptions are formoterol, salbutamol, fenoterol, salmeterol and terbutaline which can be used by athletes if a proper medical justification (TUE) is issued. Although this group of medication is frequently declared by athletes on the doping control forms these substances are not always detected. In addition, no minimum required performance levels (MRPL) for laboratories have been presently issued by WADA. Information about the excretion of beta-2-agonists in urine after the use by different administration routes could result in the establishment of MRPL levels based upon scientific evidence. Therefore this project will focus on the administration of different beta-2-agonists by different administration routes. In this project 5 beta-2-agonists will be administered (i.e. salbutamol, formoterol, fenoterol, salmeterol and terbutaline) of which 2 of them will be administered both by inhalation and orally. All these studies will be conducted following a strict research protocol as approved by an ethical committee. As the supposed outcome of this research is a MRPL level, the first step of this project is to develop and validate quantitative analytical methods for all administered beta-2-agonists (except salbutamol for which these methods already exist).
    [Show full text]
  • Dry Powder Inhalers Comprising a Carrier Other Than Lactose
    (19) TZZ Z T (11) EP 2 682 097 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 A61K 9/00 (2006.01) A61K 9/14 (2006.01) A61K 31/40 (2006.01) A61K 31/439 (2006.01) (2006.01) (21) Application number: 13175077.0 A61K 31/4704 (22) Date of filing: 04.07.2013 (84) Designated Contracting States: • Türkyilmaz, Ali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 34460 Istanbul (TR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Mutlu, Onur PL PT RO RS SE SI SK SM TR 34460 Istanbul (TR) Designated Extension States: BA ME (74) Representative: Sevinç, Erkan Istanbul Patent & Trademark (30) Priority: 05.07.2012 TR 201207842 Consultancy Ltd. Plaza 33, Buyukdere Cad. No: 33/16 (71) Applicant: Arven Ilac Sanayi Ve Ticaret A.S. Sisli Istanbul 34460 (TR) 34381 Istanbul (TR) (72) Inventors: • Cifter, Ümit 34460 Istanbul (TR) (54) Dry Powder Inhalers Comprising A Carrier Other Than Lactose (57) This invention relates to novel pharmaceutical other obstructive airways diseases. In addition, the compositions for inhalation comprising separately, se- present invention relates to novel pharmaceutical com- quentially or together, drugs having amine in the form of position for inhalation based on combinations of long act- a dry powder in admixture with a pharmaceutically ac- ing muscarinic antagonists, long acting beta agonists, ceptable carrier, other than lactose, and its use in the short acting beta-2 agonists, corticosteroids or a combi- treatment of respiratory condition selected from asthma nation of two or more of them.
    [Show full text]
  • Fenoterol Hydrobromide May Be Given from a Фенотерол of Short-Acting Beta2 Agonists in the Previous 1 to 5 Years
    Clenbuterol Hydrochloride/Fenoterol 1121 struction. Etamiphylline does not liberate theophylline in the Adverse Effects and Precautions 11. Sears MR, Taylor DR. The β -agonist controversy: observa- body. Etamiphylline camsilate is used in veterinary medicine. tions, explanations and relationship to asthma epidemiology. As for Salbutamol, p.1131. Drug Safety 1994; 11: 259–83. The hydrochloride salt has also been used. 12. Fuller RW. Use of β agonists in asthma: much ado about noth- Increased mortality. Since the introduction of metered-dose ing? BMJ 1994; 309: 795–6. Preparations aerosols of beta agonists there have been two reported epidemics 13. Sears MR. Asthma deaths in New Zealand. Lancet 1995; 345: Proprietary Preparations (details are given in Part 3) of increased morbidity and mortality in asthmatic patients asso- 655–6. Spain: Solufilina. ciated with their use. The first occurred in the 1960s and was 14. Tattersfield AE. Use of β agonists in asthma: much ado about linked with the use of high-dose isoprenaline inhalers.1 The use nothing? BMJ 1994; 309: 794–5. 15. Lanes SF, et al. Respiratory medications and risk of asthma of isoprenaline was subsequently largely stopped in favour of death. Thorax 2002; 57: 683–6. more selective beta2 agonists. 16. Anderson HR, et al. Bronchodilator treatment and deaths from Etofylline (BAN, rINN) The second epidemic occurred in New Zealand in the late 1970s asthma: case-control study. Abridged version: BMJ 2005; 330: 1-5 117. Full version: http://www.bmj.com/cgi/reprint/330/7483/117 Aethophyllinum; Etofilina; Etofilinas; Etofillin; Etofylin; Etofylliini; and 1980s and was associated with the use of fenoterol.
    [Show full text]
  • Multi-Discipline Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210595Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595} {Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder} NDA/BLA Multi‐Disciplinary Review and Evaluation Application Type NDA Application Number(s) 210595 Priority or Standard Standard Submit Date(s) May 31, 2018 Received Date(s) May 31, 2018 PDUFA Goal Date March 31, 2019 Division/Office Division of Pulmonary, Allergy, and Rheumatology Products Review Completion Date March 29, 2019 Established/Proper Name Aclidinium bromide/formoterol fumarate inhalation powder (Proposed) Trade Name Duaklir Pressair Pharmacologic Class Long‐acting muscarinic/Long‐acting B2‐agonist Code name Applicant AstraZenecaPharmaceuticals LP Doseage form Inhalation powder Applicant proposed Dosing One inhalation (400 µg aclidinium bromide/ 12 µg formoterol Regimen fumarate) twice daily Applicant Proposed ‐ (b) (4) maintenance treatment of (b) (4) Indication(s)/Population(s) patients with chronic obstructive pulmonary disease (COPD), (b) (4) Recommendation on Approval Regulatory Action Recommended (b) (4) maintenance treatment of patients with COPD Indication(s)/Population(s) (if applicable) Recommended Dosing One inhalation (400 µg aclidinium bromide/ 12 µg formoterol Regimen fumarate) twice daily 1 Version date: September 12, 2018 Reference
    [Show full text]
  • List Item Short-Acting Beta-Agonists Article-31 Referral
    Annex II Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation 19 Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation The CMDh considered the below PRAC recommendation dated 5 September 2013 with regards to the terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing medicinal products: 1. Overall summary of the scientific evaluation of terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing medicinal products by PRAC (see Annex I) On 27 November 2012, further to evaluation of data resulting from pharmacovigilance activities, Hungary informed the European Medicines Agency, pursuant to Article 31 of Directive 2001/83/EC, of their consideration that the risk-benefit balance of short-acting beta-agonists (SABAs) containing medicinal products authorised in obstetric indications has become unfavourable, taking into account the cardiovascular events reported. Hungary considered it was in the interest of the Union to refer the matter to the PRAC and expressed concerns with regards to the posology and warnings reflected in the product information. The short-acting beta-agonists (SABAs) (also known as beta-mimetics), salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine are all nationally authorised and have been on the market within the EU since the 1960s. Authorised obstetric indications for SABAs differ across Member States. The authorised obstetric indications include partus prematurus, tocolysis (for some products use is restricted to particular weeks of gestation but for others no specific gestation period is specified), external cephalic version (ECV), and hyper-uterine contractility.
    [Show full text]
  • Interactions Between Corticosteroids and Β Agonists
    Thorax 2000;55:595–602 595 Occasional reviews Interactions between corticosteroids and â agonists Department of Medicine, Dunedin D R Taylor, R J Hancox School of Medicine, P O Box 913, Dunedin, New Zealand D R Taylor Inhaled corticosteroids and â agonists are the whereas long acting agents are indicated as a R J Hancox most frequently prescribed drugs in the supplement to anti-inflammatory therapy if management of chronic asthma. Current breakthrough symptoms persist.1 Thus, co- Correspondence to: prescribing is commonplace. However, despite Dr D R Taylor guidelines emphasise their complementary e-mail: robin.taylor@ role. Inhaled corticosteroids are the treatment dynamic interactions between endogenous stonebow.otago.ac.nz of choice for all but the mildest of disease. glucocorticoids and catecholamines in vivo, it Received 5 January 2000 Short acting â agonists are recommended for is only recently that interest in the possibility of Accepted for publication “as required” relief of asthma symptoms, drug interactions has developed. Two topical 20 January 2000 and clinically relevant questions arise. Firstly, do positive interactions occur, thus providing s BA theoretical justification for current trends to use combination products incorporating a long Gs BR acting â agonist and a corticosteroid? Sec- AC ondly, do negative interactions occur which might explain the apparent paradox that, HSP GR 1 ATP despite increasing use of the two therapies over the last 30 years, the overall burden of asthma cAMP HSP s 2 morbidity in most western countries has GR CREB continued to increase?2 TF 3 EVects of glucocorticoids on â receptor PKA 10 function s 4 Endogenous adrenal glucocorticoids have an GR CREB important facilitatory eVect on â receptor 6 function in vivo.
    [Show full text]
  • Inhaled Β2-Agonists in Asthma Management: an Evolving Story
    Diana Silva1,2, Tiago Jacinto3,4 [email protected] 1Serviço de Imunoalergologia, Centro Hospitalar São João, EPE, Porto, Portugal. 2Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal. 3Allergology, CUF Porto Hospital and Instituto, Porto, Portugal. 4CINTESIS – Center for Research in Health Technologies and Information Systems, Faculty of Medicine, University of Porto, Porto, Portugal. Inhaled β2-agonists in asthma management: an evolving story Cite as: Silva D, Jacinto T. Inhaled β2-agonists in asthma Landmark papers in respiratory medicine management: an evolving story. Breathe 2016; 12: 379–381. From the beginning… was inadequate for control of nocturnal symptoms and limited their use for maintenance treatment [1]. Sympathomimetic agents have been known in For these reasons, long-acting β2-agonists (LABA) Chinese medicine for at least 5000 years as a drug were developed in the 1980s. to treat disorders of respiratory tract; however, they With duration of action that reached 12 h, were introduced to western medicine mainly in the formoterol and salmeterol were considered for beginning of the 20th century [1]. long-term treatment, particularly among patients Adrenaline and isoproterenol were the first who did not achieve control under regular inhaled to be introduced, although, being unselective corticosteroids. The mechanisms for their long β-agonists, they were prone to significant side- duration have been debated, and it seems that effects. Through the years, new formulations and different physicochemical properties in contact routes of administration of these drugs, namely with the cell membrane and with the β2-receptor the inhaled route, were associated with more might explain their characteristics.
    [Show full text]